New RSV shot protects thousands of babies from severe illness
NCT ID NCT06325332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well a single dose of BEYFORTUS (nirsevimab) protects infants from serious RSV infections that require a doctor visit or hospital stay. Researchers followed nearly 50,000 babies during their first RSV season. The goal was to see if the shot reduces cases of RSV-related lung infections and other medical visits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaiser Permanente Northern California: Site number 0001
Oakland, California, 94612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine given during pregnancy shield infants from a deadly virus?
- Moderna's mRNA vaccine cocktail passes early safety check
- New RSV vaccine shows promise for seniors in korea
- Could a shot during pregnancy shield babies from RSV?
- RSV booster shot shows promise for seniors
- New mRNA RSV vaccine shows promise for older adults in phase 3 trial